• About
  • Contact
  • Advertise
  • Privacy Policy
  • Terms Of Use
Sunday, July 6, 2025
No Result
View All Result
Converseer
  • Home
  • News
    • General News
    • Education
    • Business
    • Security
    • Entertainment
    • Lifestyle
    • Tourism
  • Politics
  • Metro
  • Jobs
  • Sports
  • Health
  • Tech
  • More
    • Science & Nature
    • Agriculture
    • Opinion
    • Feature
    • Fact Check
    • History
    • Profile & Biography
    • Special Reports
  • Home
  • News
    • General News
    • Education
    • Business
    • Security
    • Entertainment
    • Lifestyle
    • Tourism
  • Politics
  • Metro
  • Jobs
  • Sports
  • Health
  • Tech
  • More
    • Science & Nature
    • Agriculture
    • Opinion
    • Feature
    • Fact Check
    • History
    • Profile & Biography
    • Special Reports
No Result
View All Result
Converseer
No Result
View All Result

Germany’s BioNTech to buy Chinese firm with promising cancer drug

by Agency Reports
13 November 2024
in Health
Germany's BioNTech to buy Chinese firm with promising cancer drug

The Biontech logo can be seen on one of the company's warehouse buildings in Mainz. Credit: Sebastian Gollnow/dpa

Berlin, Germany – Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its cancer drug development by agreeing to buy Chinese firm Biotheus.

The Mainz-based group said in a statement on Wednesday it will pay up to $950 million, including an upfront payment of $800 million.

The takeover of the Chinese company with around 300 employees is expected to be completed in the first quarter of 2025.

With the acquisition, BioNTech will secure full worldwide rights to a drug candidate called BNT327, which is already at an advanced stage of clinical development.

According to BioNTech, the results of clinical trials of the drug in more than 700 patients treated for various tumour types are encouraging.

BioNTech co-founder Ugur Sahin said the company believes the active ingredient has the potential to set a new standard of treatment in certain cancers.

Several studies with the active ingredient, for example for the treatment of lung and breast cancer, are to begin this year and next.

The acquisition also provides BioNTech with a research and development centre and a production facility in China.

BioNTech is aiming for the first market approval for a cancer drug in 2026.

(dpa)

Tags: China NewsGermany News

Related News

Cross River Govt Signs UNICEF Work Plan 2025-2027
Health

Cross River Govt Signs UNICEF Work Plan 2025-2027

4 months ago
C’River Gov’t seals clinic over high rate of mother/child deaths during delivery
Health

C’River Gov’t seals clinic over high rate of mother/child deaths during delivery

1 year ago
National Sports Festival to hold January 2025
Health

UNICEF, IHS donate oxygen plant to Cross River Govt

1 year ago
WBW: C’River approves 6-months extended pay-maternity-leave for nursing, lactating mothers
Health

WBW: C’River approves 6-months extended pay-maternity-leave for nursing, lactating mothers

11 months ago
Otu flags-off health palliative programme for pregnant women, under 5 children, elderly over 70
Health

Otu flags-off health palliative programme for pregnant women, under 5 children, elderly over 70

1 year ago
Na’ar Youth Swagger to offer free medicare to over 5000 people in C’River
Health

Na’ar Youth Swagger to offer free medicare to over 5000 people in C’River

1 year ago

Latest News

Cross River Chief of Staff reaffirms loyalty to Governor Otu, donates to church

Calls intensify for NOUN study centre in Ogoja

Mbappé’s bicycle kick seals Real Madrid’s 3-2 win over Dortmund

Dr Agbor calls for unified action to combat quackery in Obudu

Community forces man to marry his 13-year-old daughter after impregnating her in Cross River

Reactions trail Imoke’s defection from PDP to ADC

About Us

Converseer is an online newspaper that delivers impartial, comprehensive news coverage on politics, business, health, tech, metro, and education, among other topics.

Social Media

  • Facebook
  • WhatsApp
  • X (Twitter)
  • YouTube
  • Telegram

Coverage

  • Africa
  • Americas
  • Asia
  • Europe
  • Middle East

Special Pages

  • Special Reports
  • Fact Check
  • Feature
  • Opinion
  • History
  • About
  • Contact
  • Advertise
  • Privacy Policy
  • Terms Of Use

© 2025 Converseer - All Rights Reserved.

No Result
View All Result
  • Home
  • News
    • General News
    • Education
    • Business
    • Security
    • Entertainment
    • Lifestyle
    • Tourism
  • Politics
  • Metro
  • Jobs
  • Sports
  • Health
  • Tech
  • More
    • Science & Nature
    • Agriculture
    • Opinion
    • Feature
    • Fact Check
    • History
    • Profile & Biography
    • Special Reports

© 2025 Converseer - All Rights Reserved.